Merck announces the results of a Phase II study evaluating zilovertamab vedotin, an investigational ADC (antibody-drug conjugate), in combination with R-CHP (cyclophosphamide, doxorubicin, prednisone, rituximab) to treat patients with untreated diffuse large B-cell lymphoma (DLBCL).

In the pre-planned analysis, zilovertamab vedotin 1.75 mg/kg combined with R-CHP demonstrated a 100% complete response (CR) rate in 15 patients, establishing this dose as recommended for phase 3.

Principal investigator Dr Muhit Ozcan emphasized the importance of these results in addressing the unmet needs of patients with DLBCL, a disease where 40% of patients relapse or become refractory after standard therapy.

Merck's Dr. Gregory Lubiniecki praised the promising preliminary results and manageable safety profile of this treatment.

Copyright (c) 2024 CercleFinance.com. All rights reserved.